The need for innovation in healthcare has arguably never been greater. A range of factors, from aging world populations to rising standards of living in developing countries, are poised to drive long-run demand for innovative drugs, devices and medical technologies that can improve outcomes and reduce costs. Ironically, however, funding for healthcare innovation remains in … Continue reading “Strategies for Navigating the Life Sciences Capital Crunch”
Author: Matthew Rossiter
Matt Rossiter is a partner with Fenwick & West, LLP in San Francisco and represents start-up companies, established public companies and venture capital investors, with particular focus on the life science industry. He seeks to provide thoughtful, practical advice to clients on a variety of corporate finance and corporate governance matters, as well as on complex commercial and intellectual property transactions. Matt is a frequent lecturer at Stanford Law School and Wharton Business School.